Methods for in vivo identification of cancer initiating cells by multimodality reporter gene imaging
US-9220793-B2 · Dec 29, 2015 · US
Imaging and therapy of virus-associated tumors
US2016354498A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016354498-A1 |
| Application number | US-201615072896-A |
| Country | US |
| Kind code | A1 |
| Filing date | Mar 17, 2016 |
| Priority date | Apr 10, 2007 |
| Publication date | Dec 8, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention features compositions and methods for detecting, selecting a treatment method for, monitoring, and treating a neoplasia associated with a viral infection.
First claim
Opening claim text (preview).
1 .- 31 . (canceled) 32 . A method for detecting an infection associated neoplasia in a subject, the method comprising administering to the subject an effective amount of a viral lytic induction agent and a radiolabeled analog of 2′-deoxy-5-iodo-I-beta-D-arabinofuranosyluracil (FIAU), and visualizing the neoplasia. 33 .- 37 . (canceled) 38 . A method for selecting a therapy for a subject having an infection associated neoplasia, the method comprising administering to the subject an effective amount of a viral lytic induction agent and a radiolabeled analog of 2′-deoxy-5-iodo-I-beta-D-arabinofuranosyluracil (FIAU); and detecting the presence or absence of lytic induction in the subject, wherein an increase in lytic induction identifies a subject as amenable to treatment with a lytic induction agent and enzyme-targeted radiation therapy. 39 .- 40 . (canceled) 41 . A method for killing a neoplastic cell infected with a virus or bacteria, the method comprising contacting the cell with an effective amount of a viral lytic induction agent and a radiolabeled analog of 2′-deoxy-5-iodo-I-beta-D-arabinofuranosyluracil (FIAU). 42 .- 63 . (canceled)
Assignees
Inventors
Classifications
Antibacterial agents · CPC title
Oxazoles · CPC title
Antivirals · CPC title
having a nitrogen attached in position 2, e.g. clonidine · CPC title
Medicinal preparations containing organic active ingredients · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016354498A1 cover?
- The present invention features compositions and methods for detecting, selecting a treatment method for, monitoring, and treating a neoplasia associated with a viral infection.
- Who is the assignee on this patent?
- Univ Johns Hopkins
- What technology area does this patent fall under?
- Primary CPC classification A61K51/0491. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Dec 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).